{"DataElement":{"publicId":"4971192","version":"1","preferredName":"Eligibility Criteria Prior Chemotherapy or Immunotherapy or Biological Agent or Hormone Therapy for Brain Tumor Other Than Gliadel Wafers Or Therapeutic Glucocorticoid  Indicator","preferredDefinition":"Eligibility criteria indicator of whether or not the patient had any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor other than prior Gliadel Wafers or glucocorticoid therapy.","longName":"BRAIN_THERAPY_IND","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"4971154","version":"1","preferredName":"Clinical Trial Eligibility Criteria Prior Chemotherapy Immunotherapy Biological Agent Endocrine Therapy Except Gliadel Wafers Or Therapeutic Glucocorticoid For Brain Neoplasm Received","preferredDefinition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._Earlier in time or order._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._Therapy designed to induce changes in a patient's immune status in order to treat disease._Biotechnology-derived pharmaceutical agents made from living organisms or their products. Includes recombinant proteins, monoclonal antibodies, and nucleic acids._Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level._An instance that does not conform to a rule or generalization._A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)_An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Synthetically derived forms of the naturally occurring Glucocorticoids._The reason of something._A benign or malignant neoplasm that arises from or metastasizes to the brain._To take, accept, or get something offered.","longName":"2767728v1.0:4971155v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"2767728","version":"1","preferredName":"Clinical Trial Eligibility Criteria","preferredDefinition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"529EA070-682D-67A0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-22","endDate":null,"createdBy":"UMLLOADER_WCI","dateCreated":"2008-07-22","modifiedBy":"ONEDATA","dateModified":"2008-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4971155","version":"1","preferredName":"Prior Chemotherapy Immunotherapy Biological Agent Endocrine Therapy Exception Polifeprosan 20 with Carmustine Implant Or Therapeutic Glucocorticoid For Brain Neoplasm Receive","preferredDefinition":"Earlier in time or order.:The use of synthetic or naturally-occurring chemicals for the treatment of diseases.:Treatment to boost or restore the ability of the immune system to fight cancer, infections, and other diseases. Also used to lessen certain side effects that may be caused by some cancer treatments. Agents used in immunotherapy include monoclonal antibodies, growth factors, and vaccines. These agents may also have a direct antitumor effect.:Biotechnology-derived pharmaceutical agents made from living organisms or their products. Includes recombinant proteins, monoclonal antibodies, and nucleic acids.:Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.:An instance that does not conform to a rule or generalization.:A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04):An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Synthetically derived forms of the naturally occurring Glucocorticoids.:The reason of something.:A benign or malignant neoplasm that arises from or metastasizes to the brain.:To take, accept, or get something offered.","longName":"4971155v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"11"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"10"},{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"9"},{"longName":"Biological Agent","conceptCode":"C307","definition":"Biotechnology-derived pharmaceutical agents made from living organisms or their products. Includes recombinant proteins, monoclonal antibodies, and nucleic acids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"8"},{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"7"},{"longName":"Exception","conceptCode":"C54420","definition":"An instance that does not conform to a rule or generalization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"6"},{"longName":"Carmustine Implant","conceptCode":"C2487","definition":"A synthetic, biodegradable wafer containing the agent carmustine with antineoplastic activity. Used to deliver drug directly into a brain tumor site and typically implanted post-surgically, the wafer is made of a biodegradable poly-anhydride copolymer and contains the nitrosourea carmustine.  As an antineoplastic nitrosourea, carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  Carmustine also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Therapeutic Glucocorticoid","conceptCode":"C521","definition":"Synthetically derived forms of the naturally occurring Glucocorticoids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"For","conceptCode":"C64956","definition":"The reason of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Brain Neoplasm","conceptCode":"C2907","definition":"A benign or malignant neoplasm that arises from or metastasizes to the brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4DDA97-4CD7-0005-E050-BB89AD43576C","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"ONEDATA","dateModified":"2015-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4DDA97-4CB2-0005-E050-BB89AD43576C","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for 1403 study in Rave per request by J.Zhao.mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280724","version":"1","longName":"Eligibility Checklist","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Has the patient received any","type":"Preferred Question Text","description":"Has the patient received any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or homonal therapy for their brain tumor other than prior Gliadel Wafers or glucocorticoid therapy?","url":null,"context":"ABTC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E612B-F41F-E22A-E050-BB89AD431F32","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeDescription":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}